- Home
- INCY
INCY
Incyte Corp.
as of 01-14-2026 2:08pm EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 17.0B | IPO Year: | 1993 |
| Target Price: | $96.79 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.90 | EPS Growth: | 3878.02 |
| 52 Week Low/High: | $53.56 - $112.29 | Next Earning Date: | 02-09-2026 |
| Revenue: | $4,813,105,000 | Revenue Growth: | 18.09% |
| Revenue Growth (this year): | 19.59% | Revenue Growth (next year): | 10.80% |
AI-Powered INCY Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Incyte Corp. (INCY)
EVP, Head of US Oncology
Avg Cost/Share
$109.07
Shares
10,856
Total Value
$1,184,063.92
Owned After
66,132
SEC Form 4
EVP & Chief Medical Officer
Avg Cost/Share
$101.70
Shares
15,634
Total Value
$1,589,977.80
Owned After
34,203
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$100.00
Shares
2,774
Total Value
$277,400.00
Owned After
22,973
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$98.25
Shares
600
Total Value
$58,950.00
Owned After
22,973
SEC Form 4
EVP, Head of Tech. Operations
Avg Cost/Share
$97.26
Shares
4,323
Total Value
$420,454.98
Owned After
27,507
SEC Form 4
EVP, Head of Tech. Operations
Avg Cost/Share
$97.36
Shares
54,008
Total Value
$5,254,546.61
Owned After
27,507
EVP & Chief Medical Officer
Avg Cost/Share
$102.51
Shares
20,105
Total Value
$2,060,963.55
Owned After
34,203
SEC Form 4
EVP & Chief Medical Officer
Avg Cost/Share
$102.96
Shares
2,559
Total Value
$263,474.64
Owned After
34,203
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$103.00
Shares
600
Total Value
$61,800.00
Owned After
22,973
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$102.00
Shares
169
Total Value
$17,238.00
Owned After
22,973
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Issa Mohamed Khairie | INCY | EVP, Head of US Oncology | Jan 7, 2026 | Sell | $109.07 | 10,856 | $1,184,063.92 | 66,132 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Jan 5, 2026 | Sell | $101.70 | 15,634 | $1,589,977.80 | 34,203 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 19, 2025 | Sell | $100.00 | 2,774 | $277,400.00 | 22,973 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 18, 2025 | Sell | $98.25 | 600 | $58,950.00 | 22,973 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 17, 2025 | Sell | $97.26 | 4,323 | $420,454.98 | 27,507 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 16, 2025 | Sell | $97.36 | 54,008 | $5,254,546.61 | 27,507 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Dec 2, 2025 | Sell | $102.51 | 20,105 | $2,060,963.55 | 34,203 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Dec 1, 2025 | Sell | $102.96 | 2,559 | $263,474.64 | 34,203 | |
| Tray Thomas | INCY | Principal Accounting Officer | Nov 24, 2025 | Sell | $103.00 | 600 | $61,800.00 | 22,973 | |
| Tray Thomas | INCY | Principal Accounting Officer | Nov 21, 2025 | Sell | $102.00 | 169 | $17,238.00 | 22,973 |
Compare INCY vs Leading Stocks
See how INCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.